MDAX ends Thursday 1.03% lower as US weakness weighs
Published on 11/19/2026 at 18:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMDAX retreat after early gains
- The MDAX closed Thursday at 29,572.04 points, down 1.03% from Wednesday's close.
- The index initially advanced, but weaker US markets weighed on sentiment later in the session.
- Evonik was the weakest constituent after BASF abandoned its takeover efforts, while Aixtron was among the strongest performers.
The MDAX ended Thursday's session lower after an early recovery attempt lost momentum. According to finanzen.net, the index finished at 29,572.04 points, down 1.03% from the previous session.
Early gains fade by the close
The mid-cap index opened 0.471% higher at 30,019.21 points, following Wednesday's close at 29,878.63 points. It reached an intraday high of 30,191.31 points before weakening to a low of 29,559.36 points. The closing level therefore remained close to the day's low.
The session's direction changed as US equity markets weakened. A report by finanzen.ch said that the German market fell despite enthusiasm surrounding the Anthropic initial public offering, while declining US markets pressured sentiment late in the European session.
Evonik weighs on the index
Evonik was the most prominent drag among MDAX constituents. Its shares fell more than 16% after BASF said it had ended efforts to acquire the specialty chemicals group following the rejection of two non-binding cash offers. Lanxess and AUTO1 also posted notable losses.
Technology-related stocks provided some support. Aixtron, flatexDEGIRO and Sartorius were among the session's strongest MDAX performers, according to Investing.com. The gains reflected the stronger tone in selected technology shares, although they were insufficient to offset weakness elsewhere in the index.
Investor focus remains selective
For investors, Thursday's trading highlighted the uneven response to the broader technology rebound narrative. The Anthropic listing supported several chip-related names during the session, but renewed pressure from US markets and company-specific developments in chemicals dominated the final result. The MDAX's decline also extended its recent weakness, with the index below its level from one month earlier.
